JP2006504795A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504795A5
JP2006504795A5 JP2005500374A JP2005500374A JP2006504795A5 JP 2006504795 A5 JP2006504795 A5 JP 2006504795A5 JP 2005500374 A JP2005500374 A JP 2005500374A JP 2005500374 A JP2005500374 A JP 2005500374A JP 2006504795 A5 JP2006504795 A5 JP 2006504795A5
Authority
JP
Japan
Prior art keywords
dosage
period
composition
active ingredient
twice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005500374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504795A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/031622 external-priority patent/WO2004030633A2/en
Publication of JP2006504795A publication Critical patent/JP2006504795A/ja
Publication of JP2006504795A5 publication Critical patent/JP2006504795A5/ja
Withdrawn legal-status Critical Current

Links

Images

JP2005500374A 2002-10-03 2003-10-03 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬 Withdrawn JP2006504795A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41573902P 2002-10-03 2002-10-03
US43155002P 2002-12-06 2002-12-06
US44308103P 2003-01-28 2003-01-28
US44320303P 2003-01-28 2003-01-28
PCT/US2003/031622 WO2004030633A2 (en) 2002-10-03 2003-10-03 Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010173175A Division JP2010275314A (ja) 2002-10-03 2010-07-30 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬

Publications (2)

Publication Number Publication Date
JP2006504795A JP2006504795A (ja) 2006-02-09
JP2006504795A5 true JP2006504795A5 (es) 2010-09-16

Family

ID=32074649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005500374A Withdrawn JP2006504795A (ja) 2002-10-03 2003-10-03 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
JP2010173175A Pending JP2010275314A (ja) 2002-10-03 2010-07-30 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010173175A Pending JP2010275314A (ja) 2002-10-03 2010-07-30 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬

Country Status (7)

Country Link
US (1) US20040106681A1 (es)
EP (1) EP1558231A4 (es)
JP (2) JP2006504795A (es)
AU (1) AU2003284005B2 (es)
CA (1) CA2500662A1 (es)
MX (1) MXPA05003550A (es)
WO (1) WO2004030633A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
NZ541733A (en) 2003-02-14 2009-03-31 Pf Medicament Use of the enantiomer (1S,2R) of milnacipran for the preparation of a medicament
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
US7488747B2 (en) * 2003-12-29 2009-02-10 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20080293726A1 (en) 2005-07-06 2008-11-27 Sepracor Inc. Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
AU2012203789B2 (en) * 2005-09-28 2014-12-11 Forest Laboratories Holdings Limited Milnacipran for the long-term treatment of fibromyalgia syndrome
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
NZ569608A (en) * 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
EP1976513B1 (en) * 2006-01-06 2016-08-24 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
PL2656842T3 (pl) * 2006-03-27 2017-01-31 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
EP2816024B8 (en) 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
US20090280171A1 (en) * 2006-04-13 2009-11-12 Accu-Break Technologies, Inc. Method of treatment with predictably breakable pharmaceutical tablets
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080058318A1 (en) * 2006-08-09 2008-03-06 Cypress Bioscience, Inc. Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
US20080058317A1 (en) * 2006-08-09 2008-03-06 Cypress Bioscience, Inc. Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
JP2010516697A (ja) * 2007-01-18 2010-05-20 セプラコール インク． Ｄ−アミノ酸オキシダーゼ阻害剤
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
KR101581289B1 (ko) 2007-05-31 2015-12-31 세프라코 아이엔시. 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP2496079A4 (en) 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS
CN102883601A (zh) 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
CA2818491A1 (en) * 2010-11-18 2012-05-24 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
LT3054950T (lt) 2014-05-09 2017-11-27 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (r)-pirlindolas ir jo farmaciniu požiūriu priimtinos druskos, skirti naudoti medicinoje
ES2988983T3 (es) * 2014-05-09 2024-11-22 Tecnimede Sociedade Tecnico Medicinal S Sales de mandelato de enantiómeros de pirlindol para uso en medicina
NO3057589T3 (es) * 2014-05-09 2017-12-30
US20180333365A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352683A (en) * 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
CA2289190A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
ES2247572T3 (es) * 1999-07-01 2006-03-01 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar las cefaleas migrañosas.
WO2001012184A1 (en) * 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Neurotherapeutic composition and method
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
US20020147196A1 (en) * 2001-04-05 2002-10-10 Quessy Steven Noel Composition and method for treating neuropathic pain
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030203055A1 (en) * 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
CA2503121A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20060024366A1 (en) * 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
WO2006023702A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders with setiptiline
WO2007012064A2 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome

Similar Documents

Publication Publication Date Title
JP2006504795A5 (es)
JP2009525343A5 (es)
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2014526503A5 (es)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
EP2248519A3 (en) Non-mucoadhesive film dosage forms
JP2009543885A5 (es)
JP2013231087A5 (es)
JP2007238598A5 (es)
JP2012193216A5 (es)
JP2009504774A5 (es)
RU2006101225A (ru) Пероральные лекарственные формы мемантина
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
JP2006513184A5 (es)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
JP2013544290A5 (es)
JP2013536837A5 (es)
JP2005068010A5 (es)
RU2002122084A (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
JP2011500589A5 (es)